Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Alto Neuroscience, Inc.

35 indications, side-by-side phase, drug & LoA

$21.47

+0.04 (+0.19%)

C 50Pipeline Score Fair Value Biotech · Commercial
Market Cap
744.69 M
EPS
-2.48
P/E Ratio
-
Value Trade
8.87 M
SEC Financials
Q1 2026

  • Dilution Risk

    15%

  • R&D Expenses

    20.29 M

  • Operating CF

    -27.09 M

  • Total Assets

    276.26 M

  • Total Liabilities

    32.89 M

  • Equity

    243.37 M

  • D/E Ratio

    12,345

-7.9 %
Week
-19.07 %
1 Month
10.06 %
3 Month
51.25 %
6 Month
-3.55 %
5 Year
-3.55 %
All Time
Cash Data
Healthy

  • Cash Position

    263.76 M

  • Monthly Burn

    9.03 M

  • Runway

    28.3 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 13, 2026
Overview
Volume
272.05 K
52 Week Range
2.15 - 28.44
% held by Insiders
10.55 %
% held by Institutions
76.74 %
Enterprise Value
504.15 M
Total Shares
31.93 M
Short %
7.07 %
Float Shares
23.95 M
Company Description
HQ: 650 CASTRO STREET, SUITE 450, ...
Employees:68
https://www.altoneuroscience.c...

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 2b topline data readout example
ALTO-300 Major Depressive Disorder (MDD)
Phase 2b
—
Small Molecules
Psychiatric Disorders
ALTO-300 Major Depressive Disorder (MDD)
Phase 2b
—
Small Molecules
Psychiatric Disorders
ALTO-300 Major Depressive Disorder (MDD)
Phase 2b
—
Small Molecules
Psychiatric Disorders
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C50
Pipeline Score
$631M
Pipeline Value
Fair Value
Valuation Signal
5
Drugs Scored
2.8x
rNPV / MCap
Top 72%
Micro Cap
(rank 254 of 905)
Percentile Rank
Alto Neuroscience, Inc. carries a moderate pipeline score (50/100), with $1.6B risk-adjusted pipeline value, led by ALTO-203 25 μg in Major Depressive Disorder (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
ALTO-203 25 μg
Small molecule		Major Depressive DisorderPhase 2NCT0639159324% $532M COMPLETED 69 - -Apr 21, 2025 -Apr 17, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
ALTO-203
major depressive disorder
Phase 2
2025-06-26
ALTO-203
major depressive disorder
Phase 2
2025-06-26
ALTO-203
major depressive disorder
Phase 2
2025-06-26
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ANRO
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ANRO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ANRO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ANRO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
ANRO Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
ANRO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-18 0.00 0 - - - - - -
2026-06-18 0.00 0 - - - - - -
2026-06-18 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Alto Neuroscience, Inc. (ANRO) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How ANRO ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Cognitive Disorders #1 of 3 PHASE 2 ALTO-101
LLY RYTM
—0.99 LEADER
Bipolar Disorder #8 of 12 PHASE 2 ALTO-100
BMY ABBV ALKS
$10.5B 0.99 FOLLOWER
Schizophrenia #12 of 15 PHASE 2 ALTO-101
NBIX BMY ALKS
$2.5B 0.99 FOLLOWER
Major Depressive Disorder #16 of 31 PHASE 2 ALTO-300
CMPS NBIX JNJ
$12.0B 0.99 FOLLOWER